The Cancer Biotherapy Research Group – Developmental Therapeutics Review – Q1 2011

Summary

The Company pharmaceuticals report, “The Cancer Biotherapy Research Group – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from The Company proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by The Company team of industry experts.

Scope

- Review of therapeutics under development by The Cancer Biotherapy Research Group.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The Cancer Biotherapy Research Group with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of The Cancer Biotherapy Research Group’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in The Cancer Biotherapy Research Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate The Cancer Biotherapy Research Group’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of The Cancer Biotherapy Research Group in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with The Cancer Biotherapy Research Group.
- Avoid Intellectual Property Rights related issues. 
 

2
List of Tables 4
List of Figures 4
The Cancer Biotherapy Research Group Snapshot 5
Key Facts 5
The Cancer Biotherapy Research Group – Research and Development Overview 6
Key Therapeutic Areas 6
The Cancer Biotherapy Research Group – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products –  Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
The Cancer Biotherapy Research Group – Pipeline Products Glance 12
The Cancer Biotherapy Research Group Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
The Cancer Biotherapy Research Group – Drug Profiles 14
Aldesleukin 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Aldesleukin + Recombinant Interferon Alfa 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Aldesleukin + Recombinant interferon alfa + Lymphocytes 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Aldesleukin + Recombinant Interferon Alfa + Therapeutic Tumor Infiltrating Lymphocytes + Cimetidine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Autologous Tumor Cell Vaccine + Recombinant Interferon Gamma 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Autologous Tumor Cell Vaccine + Sargramostim 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Gemcitabine + 5-Fluorouracil + Interleukin-2 + Alpha Interferon 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Interferon alfa + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Vincristine sulfate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Isotretinoin + Interferon alpha-2a 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Isotretinoin + Recombinant Interferon Alfa 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Recombinant Interferon Alfa 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Rituximab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Rituximab + Cyclophosphamide 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Rituximab + Cyclophosphamide + Doxorubicin hydrochloride + Prednisone + Vincristine sulfate 29
Product Description 29
Mechanism of Action 29
R&D Progress 30
Rituximab + Cyclophosphamide + Pentostatin 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Rituximab + Dexamethasone 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
The Cancer Biotherapy Research Group – Pipeline Analysis 33
The Cancer Biotherapy Research Group – Pipeline Products by Therapeutic Class 33
The Cancer Biotherapy Research Group - Pipeline Products By Target 34
The Cancer Biotherapy Research Group – Pipeline Products by Route of Administration 35
The Cancer Biotherapy Research Group – Pipeline Products by Molecule Type 36
The Cancer Biotherapy Research Group - Dormant Projects 37
The Cancer Biotherapy Research Group – Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 40
Contact Us 40
Disclaimer 40

List of Tables
The Cancer Biotherapy Research Group – Pipeline by Therapy Area and Indication, 2011 7
The Cancer Biotherapy Research Group – Pipeline by Stage of Development, 2011 9
The Cancer Biotherapy Research Group – Monotherapy Products in Pipeline, 2011 10
The Cancer Biotherapy Research Group – Combination Treatment Modalities in Pipeline, 2011 11
The Cancer Biotherapy Research Group - Phase II, 2011 12
The Cancer Biotherapy Research Group - Pipeline By Therapeutic Class, 2011 33
The Cancer Biotherapy Research Group - Pipeline By Target, 2011 34
The Cancer Biotherapy Research Group – Pipeline By Route of Administration, 2011 35
The Cancer Biotherapy Research Group – Pipeline By Molecule Type, 2011 36
The Cancer Biotherapy Research Group - Dormant Developmental Projects, 2010 37

List of Figures
The Cancer Biotherapy Research Group  – Pipeline by Therapy Area and Indication, 2011 7
The Cancer Biotherapy Research Group  – Pipeline by Stage of Development, 2011 9
The Cancer Biotherapy Research Group – Monotherapy Products in Pipeline, 2011 10
The Cancer Biotherapy Research Group – Combination Treatment Modalities in Pipeline, 2011 11
The Cancer Biotherapy Research Group  – Pipeline By Therapeutic Class, 2011 33
The Cancer Biotherapy Research Group  - Pipeline By Target, 2011 34
The Cancer Biotherapy Research Group  – Pipeline By Route of Administration, 2011 35
The Cancer Biotherapy Research Group  – Pipeline By Molecule Type, 2011 36